Clinical Trials Browser

Phase 2 × Unknown × cemiplimab × Clear all

Squamous Cell Carcinoma of Head and Neck

NCT05429866 2023-03-08

Immunological Variables Associated to ICI Toxicity in Cancer Patients

BreastDermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

Clinical Trials

A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC

Immunological Variables Associated to ICI Toxicity in Cancer Patients